Miniatura

Fitxers

Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx a cost-effectiveness.pdf (1.52 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-10-23

Llicència de publicació

cc by-nc-nd (c) Isla, Dolores et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/216391

Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1080/13696998.2024.2413289

Resum

ObjectiveLiquid biopsy (LB) is a non-invasive technique to detect genetic alterations by next-generation sequencing (NGS) when tissue biopsy is not available. This study aims to estimate in the Spanish setting, the cost-effectiveness of using FoundationOne Liquid CDx (F1L CDx), a novel blood-derived LB test based on NGS, versus non-molecular diagnosis (non-mDx) in patients with advanced non-small cell lung cancer (NSCLC) in whom tissue sampling is not feasible.MethodsA joint model was developed combining a decision-tree with partitioned survival models to calculate the costs and health outcomes over a lifetime horizon, comparing F1L CDx in LB versus non-mDx. Only direct costs (expressed in of 2023) were included and a 3% discount rate for future costs and effects was considered. Health outcomes were expressed in Life Years (LYs) and Quality-Adjusted Life Years (QALYs). Utilities and treatment efficacy were obtained from the literature. An expert panel of 11 Spanish oncologists determined the treatment allocation and validated all model inputs and assumptions. Several sensitivity analyses were performed to assess the robustness of the results.ResultsIn a hypothetical cohort of 1,000 patients, LB using F1L CDx would detect 386 alterations, so those patients could be treated with targeted therapies or enrolled in clinical trials. Cost-effectiveness results showed that F1L CDx provides greater effectiveness than non-mDx (+383.95 LYs and +305.94 QALYs), with an additional cost of 2,898,308. The incremental cost-utility ratio was 9,473/QALY gained. The probabilistic sensitivity analysis confirmed the robustness of the cost-effectiveness results.LimitationsVarious limitations inherent to cost-effectiveness analyses were described.ConclusionLB with F1L CDx test is a cost-effective strategy in Spain for patients with advanced NSCLC without tissue sample available for molecular diagnosis, improving the personalized treatment of these patients.

Matèries

Càncer de pulmó, Biòpsia, Assaigs clínics

Matèries (anglès)

Lung cancer, Biopsy, Clinical trials

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ISLA, Dolores, ÁLVAREZ, Rosa, ARNAL, María, ARRIOLA, Edurne, AZKARATE, Aitor, AZKONA, Eider, GARCÍA CAMPELO, Rosario, GARRIDO, Pilar, NADAL, Ernest, ORTEGA, Ana l., CARCEDO, David, CRESPO, María, LAVARA, Jesús, CÓRCOLES, Fernando, BERNABÉ, Reyes. Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis. _Journal of Medical Economics_. 2024. Vol. 27, núm. 1, pàgs. 1379-1387. [consulta: 21 de gener de 2026]. ISSN: 1941-837X. [Disponible a: https://hdl.handle.net/2445/216391]

Exportar metadades

JSON - METS

Compartir registre